Sentinel Node Navigation in Gastric Cancer: Where Do We Stand?
Gastric cancer
Lymphadenectomy
Minimally invasive surgery
Sentinel lymph node
Sentinel node navigation
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
1
3
2019
medline:
30
8
2019
entrez:
1
3
2019
Statut:
ppublish
Résumé
Early gastric cancer (EGC) is more common nowadays and is related a to low percentage of lymph node metastasis. For this reason, there is enormous interest to implicate minimally invasive approaches. Recently, special efforts have been made towards a potential intraoperative (real-time) lymph node metastasis (LNM) assessment, as nodal disease status could not be identified with precision before or during surgery. In this direction, accurate prediction of the LNM status through sentinel LN mapping has been attempted, as an approach to the intraoperative detection of sentinel lymph nodes (SLNs). A careful literature search was conducted in order to clarify the potential clinical application of SN biopsy in the gastric cancer field. The real clinical application of SN biopsy in gastric cancer treatment has been more than challenging due to the "complicated" nature of gastric lymphatic drainage and the high possibility of "skip" metastasis phenomenon. Notably, sophisticated technical aspects, such as the preferred tracer used and the potential "ideal" method to verify the presence of metastases in the resected SLNs, made SN biopsy application in gastric cancer field extremely demanding. Assessing the potential role of SN navigation for gastric cancer treatment in the era of advanced technology, where the minimally invasive surgical approaches are in the top of the scientific interest, it has to be highlighted that SN navigation for gastric cancer is a topic that remains highly controversial, and the need for future clinical trials on this topic is obvious.
Sections du résumé
BACKGROUND
BACKGROUND
Early gastric cancer (EGC) is more common nowadays and is related a to low percentage of lymph node metastasis. For this reason, there is enormous interest to implicate minimally invasive approaches. Recently, special efforts have been made towards a potential intraoperative (real-time) lymph node metastasis (LNM) assessment, as nodal disease status could not be identified with precision before or during surgery. In this direction, accurate prediction of the LNM status through sentinel LN mapping has been attempted, as an approach to the intraoperative detection of sentinel lymph nodes (SLNs). A careful literature search was conducted in order to clarify the potential clinical application of SN biopsy in the gastric cancer field.
CONCLUSION
CONCLUSIONS
The real clinical application of SN biopsy in gastric cancer treatment has been more than challenging due to the "complicated" nature of gastric lymphatic drainage and the high possibility of "skip" metastasis phenomenon. Notably, sophisticated technical aspects, such as the preferred tracer used and the potential "ideal" method to verify the presence of metastases in the resected SLNs, made SN biopsy application in gastric cancer field extremely demanding. Assessing the potential role of SN navigation for gastric cancer treatment in the era of advanced technology, where the minimally invasive surgical approaches are in the top of the scientific interest, it has to be highlighted that SN navigation for gastric cancer is a topic that remains highly controversial, and the need for future clinical trials on this topic is obvious.
Identifiants
pubmed: 30815770
doi: 10.1007/s12029-019-00217-w
pii: 10.1007/s12029-019-00217-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-206Références
Surg Today. 1999;29(8):695-700
pubmed: 10483741
Surg Clin North Am. 2000 Dec;80(6):1799-809
pubmed: 11140874
Surgery. 2001 Mar;129(3):335-40
pubmed: 11231462
Br J Surg. 2003 Feb;90(2):178-82
pubmed: 12555293
Am J Surg. 2004 Feb;187(2):270-3
pubmed: 14769318
Ann Surg. 2004 Mar;239(3):383-7
pubmed: 15075656
Br J Surg. 2004 May;91(5):575-9
pubmed: 15122608
Arch Surg. 1992 Apr;127(4):392-9
pubmed: 1558490
J Surg Oncol. 2005 Jun 1;90(3):147-51; discussion 151-2
pubmed: 15895450
Ann Surg. 2006 Mar;243(3):341-7
pubmed: 16495698
Ann Surg Oncol. 2006 Sep;13(9):1168-74
pubmed: 16924376
Ann Surg Oncol. 2007 Jul;14(7):2028-35
pubmed: 17453300
J Laparoendosc Adv Surg Tech A. 2008 Jun;18(3):357-63
pubmed: 18503367
J Exp Clin Cancer Res. 2008 May 30;27:7
pubmed: 18577253
Gastric Cancer. 2008;11(3):134-48
pubmed: 18825308
Ann Surg Oncol. 2009 Mar;16(3):603-8
pubmed: 19127361
Ann Surg Oncol. 2011 Jan;18(1):160-5
pubmed: 20652640
World J Gastrointest Surg. 2011 Sep 27;3(9):131-7
pubmed: 22007282
Ann Surg Oncol. 2012 May;19(5):1541-50
pubmed: 22048632
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
J Gastric Cancer. 2012 Mar;12(1):7-12
pubmed: 22500258
Ann Surg Oncol. 2013 Feb;20(2):542-6
pubmed: 22941164
Hepatogastroenterology. 2013 Sep;60(126):1513-8
pubmed: 23635507
Gastric Cancer. 2014 Apr;17(2):316-23
pubmed: 23933782
J Clin Oncol. 2013 Oct 10;31(29):3704-10
pubmed: 24019550
Eur J Surg Oncol. 2014 Jul;40(7):843-9
pubmed: 24613744
World J Gastroenterol. 2014 May 21;20(19):5685-93
pubmed: 24914329
Gastric Cancer. 2015 Apr;18(2):210-7
pubmed: 25433568
Eur J Surg Oncol. 2015 Mar;41(3):339-45
pubmed: 25454830
J Surg Res. 2016 Jan;200(1):73-81
pubmed: 26233688
Medicine (Baltimore). 2015 Oct;94(43):e1894
pubmed: 26512607
Ann Surg Oncol. 2016 Dec;23(13):4247-4252
pubmed: 27364500
Langenbecks Arch Surg. 2017 Feb;402(1):27-32
pubmed: 27999935
Transl Gastroenterol Hepatol. 2016 Dec 23;1:91
pubmed: 28138656
Ann Surg. 1989 Nov;210(5):596-602
pubmed: 2818028
Surg Endosc. 2018 Jun;32(6):2620-2631
pubmed: 29484554
Ann Surg. 1998 May;227(5):645-51; discussion 651-3
pubmed: 9605656